Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a Phase 3 clinical trial to evaluate the safety and efficacy of a new treatment combination for follicular lymphoma, a common type of B-cell cancer. The study, titled ‘A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2),’ aims to assess adverse events and changes in disease activity in adults with previously untreated follicular lymphoma.
The trial tests the combination of subcutaneous epcoritamab with intravenous rituximab and oral lenalidomide (R2), compared to standard chemoimmunotherapy options. Epcoritamab is an investigational drug designed to improve treatment outcomes for follicular lymphoma patients.
This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as its primary purpose. It involves multiple treatment arms, including combinations of epcoritamab with R2 and other chemoimmunotherapy regimens.
The study began on February 5, 2024, with an expected primary completion date not yet reached. The latest update was submitted on August 4, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AbbVie’s and Genmab’s market positions by potentially offering a new treatment option for follicular lymphoma, influencing investor sentiment positively. The success of this trial may also affect the competitive landscape in the oncology sector.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.